首页 › 急性髓系白血病 › 加利福尼亚州 › Orange
Orange CA 急性髓系白血病临床试验
13项针对 急性髓系白血病的研究正在 Orange及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
招募中2 期
- UCI Health Chao Family Comprehensive Cancer Center, Orange
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
招募中3 期
- Children's Hospital of Orange County, Orange
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Children's Hospital of Orange County, Orange
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
招募中1 期
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
招募中3 期
- Children's Hospital of Orange County Main Campus - Orange, Orange
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
招募中3 期
- University of California, Irvine, Orange
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
招募中1 期
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
招募中4 期
- UCI Irvine Health, Orange
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中观察性研究
- Children's Hospital of Orange County (CHOC), Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
其他城市的 急性髓系白血病试验
- Houston, TX85 项研究
- New York City, NY51 项研究
- Boston, MA44 项研究
- Seattle, WA41 项研究
- Baldwin Park, CA40 项研究
- Columbus, OH35 项研究
- Philadelphia, PA34 项研究
- Durham, NC33 项研究
- Atlanta, GA31 项研究
- Tampa, FL29 项研究
- Chicago, IL26 项研究
- Portland, OR25 项研究
Orange的其他研究
- 非小细胞肺癌25 项研究
- 转移性癌症20 项研究
- 结直肠癌16 项研究
- 卵巢癌16 项研究
- 胰腺癌15 项研究
- 黑色素瘤14 项研究
- 肝癌（肝细胞癌）14 项研究
- 乳腺癌14 项研究
- 肺癌14 项研究
- 前列腺癌14 项研究
- 胃癌13 项研究
- 癌症（所有类型）13 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。